Compare WKEY & XOMAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WKEY | XOMAP |
|---|---|---|
| Founded | 1999 | N/A |
| Country | Switzerland | United States |
| Employees | N/A | 13 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.4M | N/A |
| IPO Year | N/A | N/A |
| Metric | WKEY | XOMAP |
|---|---|---|
| Price | $7.83 | $26.75 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.50 | N/A |
| AVG Volume (30 Days) | ★ 356.3K | N/A |
| Earning Date | 09-23-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,994,000.00 | N/A |
| Revenue This Year | $32.29 | N/A |
| Revenue Next Year | $89.83 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.46 | N/A |
| 52 Week High | $19.80 | N/A |
| Indicator | WKEY | XOMAP |
|---|---|---|
| Relative Strength Index (RSI) | 40.44 | 56.44 |
| Support Level | $8.25 | $26.50 |
| Resistance Level | $10.05 | $26.85 |
| Average True Range (ATR) | 0.83 | 0.17 |
| MACD | -0.08 | 0.01 |
| Stochastic Oscillator | 1.33 | 78.62 |
WISeKey International Holding Ltd is a cybersecurity company focused on delivering integrated security solutions for the Internet of Things and digital identity ecosystems. It integrates secure semiconductors, cybersecurity software, and a globally recognized Root of Trust (RoT) into products and services that protect users, devices, data and transactions in the internet-connected world. It has two business segments. The IoT segment, which is the key revenue driver, generates revenue from the sale of semiconductor's secure chips. The mPKI segment generates revenues from Digital Certificates, It derives maximum revenue from IoT segment.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.